Jessica Hopfield
Jessica Hopfield's purchase track record
Jessica Hopfield has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/13/2024 | EDIT | $254K | -31.4% | -42.2% | +14.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Maravai LifeSciences Releases Q2 2026 Earnings Call Transcript. Maravai LifeSciences has published the full transcript of its second-quarter 2026 earnings call. This document provides detailed management commentary on recent operational performance and financial results. The release serves as a primary source for investors seeking to understand the company's current strategic direction and outlook.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Editas Medicine upgraded to Buy with $5 price target. Guggenheim upgraded Editas Medicine to Buy and set a $5 price target, citing a planned BLA filing in 2027 and progress with PM647. This move came as gene-editing stocks faced broader pressure from recent AI-related news. The upgrade aligns with the current average analyst target of $5.90, providing a positive fundamental signal for the stock.
Transaction History
| PODD | ▲ Buy | Grant | 1,660 | $0 | 5/20/2026 | View on chart |
| MRVI | ▲ Buy | Grant | 89,139 | $193K | 6/16/2025 | View on chart |
| PODD | ▲ Buy | Grant | 778 | $0 | 5/22/2025 | View on chart |
| PODD | ▲ Buy | Option Exercise | 5,235 | $151K | 5/13/2025 | View on chart |
| PODD | ▼ Sell | Open Market | 5,235 | $1.7M | 5/13/2025 | View on chart |
| PODD | ▲ Buy | Option Exercise | 7,628 | $228K | 9/11/2024 | View on chart |
| PODD | ▼ Sell | Open Market | 7,628 | $1.7M | 9/11/2024 | View on chart |
| MRVI | ▲ Buy | Grant | 20,645 | $223K | 5/23/2024 | View on chart |
| PODD | ▲ Buy | Grant | 1,380 | $0 | 5/22/2024 | View on chart |
| EDIT | ▲ Buy | Open Market | 45,000 | $254K | 5/13/2024 | View on chart |
| MRVI | ▲ Buy | Grant | 24,000 | $0 | 7/17/2023 | View on chart |
| PODD | ▲ Buy | Grant | 843 | $0 | 5/23/2023 | View on chart |
| PODD | ▲ Buy | Grant | 1,009 | $0 | 5/24/2022 | View on chart |
| MRVI | ▲ Buy | Grant | 4,271 | $0 | 11/19/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Insulet Sets Q3 2026 Earnings Date for Nov 4
Insulet has scheduled its third-quarter 2026 financial results for release on November 4, 2026. Recent commentary suggests the company offers affordable growth supported by strong fundamentals. The stock is currently trading near its 52-week low, with technical indicators showing a support rejection and volume spike.
Insulet Sets Q3 2026 Earnings Date for Nov 4. Insulet has scheduled its third-quarter 2026 financial results for release on November 4, 2026. Recent commentary suggests the company offers affordable growth supported by strong fundamentals. The stock is currently trading near its 52-week low, with technical indicators showing a support rejection and volume spike.